Atypical depression: A comprehensive review

CNS Drugs

Volumn 23, Issue 12, 2009, Pages 1023-1037

  Pae, Chi Un ^a,b   Tharwani, Haresh ^b   Marks, David M ^b   Masand, Prakash S ^b   Patkar, Ashwin A ^b  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CHROMIUM; CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GEPIRONE; GROWTH HORMONE; HORMONE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; IPRONIAZID; ISOCARBOXAZID; MELATONIN; MIRTAZAPINE; MOCLOBEMIDE; MODAFINIL; MONOAMINE OXIDASE A INHIBITOR; NORTRIPTYLINE; PHENELZINE; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE; UNINDEXED DRUG; VENLAFAXINE;

ATYPICAL DEPRESSION; BRAIN FUNCTION; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SUBSTITUTION; EPIDEMIOLOGICAL DATA; HEMISPHERE; HORMONE ACTION; HUMAN; HYPERTENSIVE CRISIS; MENTAL DISEASE; MOOD CHANGE; NEUROBIOLOGY; PRIORITY JOURNAL; PSYCHOBIOLOGY; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL ASPECT; RELAPSE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS;

EID: 71449108646     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11310990-000000000-00000     Document Type: Review

References (90)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association, 2000
2. Parker G, Roy K, Mitchell P, et al. Atypical depression: a reappraisal. Am J Psychiatry 2002 Sep; 159 (9): 1470-1479
3. Benazzi F. Testing DSM-IV definition of atypical depres-sion. Ann Clin Psychiatry 2003 Mar; 15 (1): 9-16
4. Horwath E, Johnson J, Weissman MM, et al. The validity of major depression with atypical features based on a community study. J Affect Disord 1992 Oct; 26 (2): 117-125
5. Novick JS, Stewart JW, Wisniewski SR, et al. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J Clin Psychiatry 2005 Aug; 66 (8): 1002-1011
6. Angst J, Gamma A, Sellaro R, et al. Toward validation of atypical depression in the community: results of the Zurich cohort study. J Affect Disord 2002 Nov; 72 (2): 125-138
7. Stewart JW, McGrath PJ, Quitkin FM. Do age of onset and course of illness predict different treatment outcome among DSM IV depressive disorders with atypical features? Neuropsychopharmacology 2002 Feb; 26 (2): 237-245
8. Kendler KS, Eaves LJ, Walters EE, et al. The identifica-tion and validation of distinct depressive syndromes in a population-based sample of female twins. Arch Gen Psychiatry 1996 May; 53 (5): 391-399
9. Zisook S, Shuchter SR, Gallagher T, et al. Atypical depression in an outpatient psychiatric population. Depression 1993; 1: 268-274
10. Thase ME. Recognition and diagnosis of atypical depres-sion. J Clin Psychiatry 2007; 68 Suppl. 8: 11-16
11. Alpert JE, Uebelacker LA, McLean NE, et al. Social phobia, avoidant personality disorder and atypical depression: cooccurrence and clinical implications. Psychol Med 1997 May; 27 (3): 627-633
12. Marcus SM, Young EA, Kerber KB, et al. Gender differ-ences in depression: findings from the STAR*D study. J Affect Disord 2005 Aug; 87 (2-3): 141-150
13. Levitan RD, Lesage A, Parikh SV, et al. Reversed neuro-vegetative symptoms of depression: a community study of Ontario. Am J Psychiatry 1997 Jul; 154 (7): 934-940
14. Asnis GM, McGinn LK, Sanderson WC. Atypical depres-sion: clinical aspects and noradrenergic function. Am J Psychiatry 1995 Jan; 152 (1): 31-36
15. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl 1993; 163 Suppl. 21: 30-34
16. McGinn LK, Asnis GM, Rubinson E. Biological and clinical validation of atypical depression. Psychiatry Res 1996 Mar 29; 60 (2-3): 191-198
17. Geracioti Jr TD, Loosen PT, Orth DN. Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression. Biol Psychiatry 1997 Aug 1; 42 (3): 165-174
18. West ED, Dally PJ. Effect of iproniazid in depressive syn-dromes. Br Med J 1959; 1: 1491-1494
19. Quitkin FM, McGrath PJ, Stewart JW, et al. Phenelzine and imipramine in mood reactive depressives: further delineation of the syndrome of atypical depression. Arch Gen Psychiatry 1989 Sep; 46 (9): 787-793
20. Nierenberg AA, Alpert JE, Pava J, et al. Course and treat-ment of atypical depression. J Clin Psychiatry 1998; 59 Suppl. 18: 5-9
21. Bruder GE, Stewart JW, McGrath PJ, et al. Atypical de-pression: enhanced right hemispheric dominance for perceiving emotional chimeric faces. J Abnorm Psychology 2002 Aug; 111 (3): 446-454
22. Fotiou F, Fountoulakis KN, Iacovides A, et al. Pattern-reversed visual evoked potentials in subtypes of major depression. Psychiatry Res 2003 Jun 15; 118 (3): 259-271
23. Fountoulakis KN, Iacovides A, Gerasimou G, et al. The relationship of regional cerebral blood flow with subtypes of major depression. Prog Neuropsychopharmacology Biol Psychiatry 2004 May; 28 (3): 537-546
24. Parker GB. Atypical depression: a valid subtype? J Clin Psychiatry 2007; 68 Suppl. 3: 18-22
25. Sargant W. Some newer drugs in the treatment of depression and their relation to other somatic treatments. Psychso-matics 1960; 1: 14-17
26. Robinson DS, Nies A, Ravaris CL, et al. The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive-anxiety states: a controlled clinical trial. Arch Gen Psychiatry 1973 Sep; 29 (3): 407-413
27. Quitkin F, Rifkin A, Klein DF. Monoamine oxidase in-hibitors: a review of antidepressant effectiveness. Arch Gen Psychiatry 1979 Jul; 36 (7): 749-760
28. Davidson JR, Miller RD, Turnbull CD, et al. Atypical de-pression. Arch Gen Psychiatry 1982 May; 39 (5): 527-534
29. Quitkin FM, Stewart JW, McGrath PJ, et al. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988 Mar; 145 (3): 306-311
30. Posternak MA, Zimmerman M. Partial validation of the atypical features subtype of major depressive disorder. Arch Gen Psychiatry 2002 Jan; 59 (1): 70-76
31. Sullivan PF, Kessler RC, Kendler KS. Latent class analysis of lifetime depressive symptoms in the National Co-morbidity Survey. Am J Psychiatry 1998 Oct; 155 (10): 1398-1406
32. Perugi G, Akiskal HS, Lattanzi L, et al. The high prevalence of ''soft'' bipolar (II) features in atypical depression. Compr Psychiatry 1998 Mar-Apr; 39 (2): 63-71
33. Robertson HA, Lam RW, Stewart JN, et al. Atypical de-pressive symptoms and clusters in unipolar and bipolar depression. Acta Psychiatr Scand 1996 Dec; 94 (6): 421-427
34. Davidson JR. A history of the concept of atypical depres-sion. J Clin Psychiatry 2007; 68 Suppl. 3: 10-15
35. Saunders JC, Radinger N, Rochlin D, et al. Treatment of depressed and regressed patients with iproniazid and re-serpine. Dis Nerv Syst 1959 Jan; 20 (1): 31-39
36. Delay J, Buisson JF. Psychic action of isoniazid in the treatment of depressive states. J Clin Exp Psychopathol 1958 Apr-Jun; 19 (2 Suppl. 1): 51-55
37. Davidson JR, Giller EL, Zisook S, et al. An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. Arch Gen Psychiatry 1988 Feb; 45 (2): 120-127
38. McGrath PJ, Stewart JW, Harrison W, et al. A placebo-controlled trial of L-deprenyl in atypical depression. Psychopharmacol Bull 1989; 25 (1): 63-67
39. Liebowitz MR, Quitkin FM, Stewart JW, et al. Phenelzine v imipramine in atypical depression: a preliminary report. Arch Gen Psychiatry 1984 Jul; 41 (7): 669-677
40. Liebowitz MR, Quitkin FM, Stewart JW, et al. Anti-depressant specificity in atypical depression. Arch Gen Psychiatry 1988 Feb; 45 (2): 129-137
41. Quitkin FM, McGrath PJ, Stewart JW, et al. Atypical de-pression, panic attacks, and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry 1990 Oct; 47 (10): 935-941
42. Quitkin FM, Harrison W, Stewart JW, et al. Response to phenelzine and imipramine in placebo nonresponders with atypical depression: a new application of the crossover design. Arch Gen Psychiatry 1991 Apr; 48 (4): 319-323
43. Pande AC, Birkett M, Fechner-Bates S, et al. Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry 1996 Nov 15; 40 (10): 1017-1020
44. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993 Jan; 150 (1): 118-123
45. Parsons B, Quitkin FM, McGrath PJ, et al. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989; 25 (4): 524-534
46. Stewart JW, Tricamo E, McGrath PJ, et al. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. Am J Psychiatry 1997 Jan; 154 (1): 31-36
47. Jarrett RB, Schaffer M, McIntire D, et al. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999 May; 56 (5): 431-437
48. Larsen JK, Gjerris A, Holm P, et al. Moclobemide in depression: a randomized, multicentre trial against iso-carboxazide and clomipramine emphasizing atypical depression. Acta Psychiatr Scand 1991 Dec; 84 (6): 564-570
49. Larsen JK, Holm P, Mikkelsen PL. Moclobemide and clo-mipramine in the treatment of depression: a randomized clinical trial. Acta Psychiatr Scand 1984 Sep; 70 (3): 254-260
50. Sogaard J, Lane R, Latimer P, et al. A 12-week study com-paring moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol 1999 Dec; 13 (4): 406-414
51. Lonnqvist J, Sihvo S, Syvalahti E, et al. Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affect Disord 1994 Nov; 32 (3): 169-177
52. McGrath PJ, Stewart JW, Janal MN, et al. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry 2000 Mar; 157 (3): 344-350
53. Stratta P, Bolino F, Cupillari M, et al. A double-blind par-allel study comparing fluoxetine with imipramine in the treatment of atypical depression. Int Clin Psychopharma-col 1991 Winter; 6 (3): 193-196
54. Joyce PR, Mulder RT, Luty SE, et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry 2002 Jun; 36 (3): 384-391
55. Pae CU, Masand PS, Peindl K, et al. An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features. Prim Care Companion J Clin Psychiatry 2008; 10 (3): 205-210
56. Henkel V, Mergl R, Allgaier AK, et al. Treatment of de-pression with atypical features: a meta-analytic approach. Psychiatry Res 2006 Jan 30; 141 (1): 89-101
57. Lecrubier Y, Pedarriosse AM, Payan C, et al. Moclobemide versus clomipramine in nonmelancholic, nonpsychotic major depression: a study group. Acta Psychiatr Scand 1995 Oct; 92 (4): 260-265
58. Dierick M, Cattiez P, Franck G, et al. Moclobemide versus clomipramine in the treatment of depression: a double-blind multicentre study in Belgium. Acta Psychiatr Scand Suppl 1990; 360: 50-51
59. Tiller J, Schweitzer I, Maguire K, et al. A sequential double-blind controlled study of moclobemide and diazepam in patients with atypical depression. J Affect Disord 1989 Mar-Jun; 16 (2-3): 181-187 (Pubitemid 19062760)
60. Schweitzer I, Tiller J, Maguire K, et al. Treatment of atypi-cal depression with moclobemide: a sequential double controlled study. Int J Clin Pharmacol Res 1989; 9 (2): 111-117 (Pubitemid 19095791)
61. Quitkin FM. Depression with atypical features: diagnostic validity, prevalence, and treatment. Prim Care Companion J Clin Psychiatry 2002 Jun; 4 (3): 94-99
62. Reimherr FW, Wood DR, Byerley B, et al. Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984; 20 (1): 70-72
63. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
64. Goodnick PJ, Extein IL. Bupropion and fluoxetine in depressive subtypes. Ann Clin Psychiatry 1989; 1: 119-122
65. Roose SP, Miyazaki M, Devanand D, et al. An open trial of venlafaxine for the treatment of late-life atypical depression. Int J Geriatr Psychiatry 2004 Oct; 19 (10): 989-994 (Pubitemid 39378294)
66. Rye DB, Dihenia B, Bliwise DL. Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion. Depress Anxiety 1998; 7 (2): 92-95
67. Stewart JW, Deliyannides DA, McGrath PJ. Is duloxetine effective treatment for depression with atypical features? Int Clin Psychopharmacol 2008 Nov; 23 (6): 333-336
68. Hyman Rapaport M. Translating the evidence on atypical depression into clinical practice. J Clin Psychiatry 2007; 68 Suppl. 3: 31-36
69. Papakostas GI, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006 Dec 15; 60 (12): 1350-1355
70. Pae CU, Lim HK, Han C, et al. Fatigue as a core symptom in major depressive disorder: overview and the role of bu-propion. Expert Rev Neurother 2007 Oct; 7 (10): 1251-1263
71. Liebowitz MR, Karoum F, Quitkin FM, et al. Biochemical effects of L-deprenyl in atypical depressives. Biol Psychiatry 1985 May; 20 (5): 558-565
72. Quitkin FM, Liebowitz MR, Stewart JW, et al. l-Deprenyl in atypical depressives. Arch Gen Psychiatry 1984 Aug; 41 (8): 777-781
73. Patkar AA, Pae CU, Masand PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr 2006 May; 11 (5): 363-375
74. Patkar AA, Pae CU, Zarzar M. Transdermal selegiline. Drugs Today (Barc) 2007 Jun; 43 (6): 361-377
75. Pae CU, Lim HK, Han C, et al. Selegiline transdermal sys-tem: current awareness and promise. Prog Neuropsycho-pharmacol Biol Psychiatry 2007 Aug 15; 31 (6): 1153-1163
76. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002 Nov; 159 (11): 1869-1875
77. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003 Feb; 64 (2): 208-214
78. Feiger AD, Rickels K, Rynn MA, et al. Selegiline transder-mal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry 2006 Sep; 67 (9): 1354-1361
79. Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol 2006 Dec; 26 (6): 579-586
80. Docherty JP, Sack DA, Roffman M, et al. A double-blind, placebo-controlled, exploratory trial of chromium picoli-nate in atypical depression: effect on carbohydrate craving. J Psychiatr Pract 2005 Sep; 11 (5): 302-314
81. Davidson JR, Abraham K, Connor KM, et al. Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol Psychiatry 2003 Feb 1; 53 (3): 261-264
82. Vaishnavi S, Gadde K, Alamy S, et al. Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. J Clin Pharmacol 2006 Aug; 26 (4): 373-378
83. Thase ME, Fava M, DeBattista C, et al. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr 2006 Feb; 11 (2): 93-102
84. DeBattista C, Doghramji K, Menza MA, et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003 Sep; 64 (9): 1057-1064
85. McGrath PJ, Stewart JW, Quitkin FM, et al. Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. J Clin Pharmacol 1994 Oct; 14 (5): 347-352
86. Murck H. Atypical depression and related illnesses: neuro-biological principles for their treatment with Hyper-icum extract [in German]. Wien Med Wochenschr 2002; 152 (15-16): 398-403
87. Leppamaki S, Partonen T, Vakkuri O, et al. Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weather-associated changes in mood and behaviour. Eur Neuro-psychopharmacol 2003 May; 13 (3): 137-145
88. Mahajan T, Crown A, Checkley S, et al. Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life. Eur J Endocrinol 2004 Sep; 151 (3): 325-332
89. Mercier MA, Stewart JW, Quitkin FM. A pilot sequen-tial study of cognitive therapy and pharmacotherapy of atypical depression. J Clin Psychiatry 1992 May; 53 (5): 166-170
90. Jarrett RB, Kraft D, Schaffer M, et al. Reducing relapse in depressed outpatients with atypical features: a pilot study. Psychother Psychosom 2000 Sep-Oct; 69 (5): 232-9